Category: Media Release

CEO Phil Lynch and CSO Daniel Tillett

1 September 2020 – Race Oncology Limited (ASX: RAC) is pleased to announce that it has expanded its executive team with the appointment of Mr Phil Lynch as Chief Executive Officer and Managing Director. Effective immediately, Mr Lynch will share…

On 16 July 2020, Race was pleased to report results of the investigator led Phase II trial of bisantrene for relapsed or refractory Acute Myleoid Leukaemia. This post summarises the highlights and provides access to key resources related to the…

Race Oncology is pleased to announce that it has entered into a collaborative preclinical research program with The University of Newcastle. Eminent cancer researcher, Associate Professor Nikki Verrills of the Hunter Medical Research Institute, will lead the project. The aim…

Race has received firm commitments for A$1.8 million (before costs) in new equity funding via a strategic placement of six million ordinary shares, at an issue price of $0.30 per share. The placement has been anchored by biotechnology-focused institutional investor…

Race Oncology is pleased to welcome highly experienced oncology clinical trials specialist Dr Marinella Messina as its Australian Clinical Program Director. Dr Messina will commence of 16 March 2020 and will be responsible for progressing the Australian trials, part of…

Race Oncology Limited is pleased to announce that Professor Borje Andersson has been appointed to the Board as a Non-Executive Director. Prof Andersson is an internationally acclaimed leader in the fields of leukaemia and stem cell transplant research at MD…

Prof Andersson is a leading researcher in the field of cancer drug development Appointment strengthens Race’s management team Prof Andersson to advise on clinical strategy, partnership initiatives and trial management 5 December 2019 – Race Oncology Limited (ASX: RAC) is honoured…

New clinical strategy targeting five cancer market segments  Expanded total addressable market for Bisantrene Bisantrene trials in AML, breast cancer, and ovarian cancer 14 November 2019 – Race Oncology Limited (ASX: RAC) today revealed its new “5 Path” clinical strategy for…

Race Oncology is pleased to announce that Dr Daniel Tillett has been appointed Chief Scientific Officer (CSO) of RAC effective from 30 September 2019. Dr Tillett recently anchored a share placement in RAC and was recently appointed as a Non-Executive…

17 September 2019 – Race Oncology Limited (ASX: RAC) is pleased to announce that prominent biotechnology investor and substantial Race shareholder, Dr Daniel Tillett, has today joined the Board of Directors of Race Oncology Ltd. Dr Daniel Tillett is the founder…